Agendia Validates Use of Its Decentralized Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing
Validation experiments were performed to assess the technical and clinical performance equivalence of the MammaPrint and Blueprint next-generation sequencing tests compared with the diagnostic microarray test.